Clinical Trials Logo

Hyperlipidemias clinical trials

View clinical trials related to Hyperlipidemias.

Filter by:

NCT ID: NCT01388816 Completed - Clinical trials for Type II Hyperlipidemia

A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels

Start date: July 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if a new drug, DRL-17822, is safe and effective in elevating high density lipoprotein cholesterol (HDL-C) and reducing low density lipoprotein cholesterol (LDL-C) in people with abnormal cholesterol levels that may put them at risk for heart disease.

NCT ID: NCT01386853 Not yet recruiting - Hyperlipidemia Clinical Trials

Efficacy and Safety Study of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients

Start date: July 2011
Phase: Phase 3
Study type: Interventional

This is a 12-week, randomized, multicenter, double-blind, active-controlled, non-inferiority study (TATPITA20101005) to compare the efficacy and safety of pitavastatin (Livalo®) and atorvastatin (Lipitor®) in high risk hypercholesterolemic patients.

NCT ID: NCT01382277 Recruiting - Clinical trials for Coronary Artery Disease

Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume

REDUCT
Start date: March 2011
Phase: Phase 4
Study type: Interventional

This multicentre, open-label, single-arm Study is to evaluate the effect of Rosuvastatin 20 mg 76 weeks on coronary atherosclerosis plaque versus baseline in Chinese coronary heart disease (CHD) patients with hyperlipidemia by measuring the plaque volume using a 64 slice spiral CT. Effect on blood lipids, hsCRP and Carotid intima-media thickness (CIMT) is also evaluated.

NCT ID: NCT01380730 Completed - Hyperlipidemia Clinical Trials

LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

LAPLACE
Start date: July 1, 2011
Phase: Phase 2
Study type: Interventional

To evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab (AMG 145) administered every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on percent change from baseline in LDL-C when used in addition to a statin in adults with hypercholesterolemia.

NCT ID: NCT01377064 Completed - Obesity Clinical Trials

Home-based Exercise for Management of HIV-associated Cardiovascular Disease Risk

Start date: March 2011
Phase: Phase 1
Study type: Interventional

Because of advances in drug treatment, people living with HIV/AIDS (PLWHA) are living longer, but are also at greater risk for cardiovascular disease (CVD) and diabetes. Exercise and increased physical activity can reduce the risk factors for these diseases in PLWHA, but no studies have tested an at-home exercise program that would benefit low income people and others who do not have access to exercise facilities. This study will test the feasibility of an at-home exercise program for PLWHA and prepare for a full-scale intervention study, which may lead to a reduction in CVD risk among PLWHA.

NCT ID: NCT01375777 Completed - Hyperlipidemia Clinical Trials

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

MENDEL
Start date: July 6, 2011
Phase: Phase 2
Study type: Interventional

The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change from baseline in LDL-C when used as monotherapy in adults with hypercholesterolemia.

NCT ID: NCT01375764 Completed - Hyperlipidemia Clinical Trials

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects

GAUSS
Start date: July 28, 2011
Phase: Phase 2
Study type: Interventional

The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia unable to tolerate an effective dose of a statin.

NCT ID: NCT01360567 Completed - Type 2 Diabetes Clinical Trials

The Effect of Green Tea Extract on Type 2 Diabetes With Hyperlipidemia

Start date: May 2011
Phase: Phase 3
Study type: Interventional

The aim of the study is to examine whether the extract of green tea is effective on type 2 diabetes and hyperlipidemia.

NCT ID: NCT01353404 Completed - Hyperlipidemia Clinical Trials

Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)

Start date: June 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the bioequivalence of Lipidil® Supra (fenofibrate 160mg) versus SYO-0805 (fenofibrate 65mg) in single dose oral administration.

NCT ID: NCT01349010 Completed - Hyperlipidemia Clinical Trials

Efficacy and Safety of Imported Probucol to Treat Hyperlipidemia

Start date: April 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of imported Probucol in hyperlipidemia patients.